Cancer Research Technology (CRT) has announced that it has signed a deal to develop a treatment called Antibody Drug Conjugates (ADCs).
The work will involve using the organisation's own antibodies and peptides in combination with ADC Therapeutics Sarl's 'warhead' and linker chemistries.
ADCs are an exciting development because they use the specificity associated with antibodies to allow powerful tumour-destroying chemicals to be internalised inside the cancer cell and avoid the surrounding healthy tissue, states the company.
Dr Phil L'Huillier, CRT's director of business management, believes this combination has already shown "promising evidence" and could be an important cancer treatment in the future.
"We hope the collaboration will identify a range of ADCs that can be taken forward for development into innovative new ways to treat cancer and save lives," he said.
According to Cancer Research UK, around 880 people are diagnosed with the disease every day in the UK